Ronald Bosch

No evidence that circulating HIV-specific immune responses contribute to persistent inflammation and immune activation in persons on long-term ART.

Ward AR, Thomas AS, Stevenson EM, Huang SH, Keating SM, Gandhi RT, McMahon DK, Bosch RJ, Macatangay BJ, Cyktor JC, Eron JJ, Mellors JW, Jones RB.

AIDS. 2022 10 01. 36(12):1617-1628. PMID: 35730388

Associations Between Multiple Measures of HIV-1 Persistence in Persons on Suppressive Antiretroviral Therapy.

Bosch RJ, Gandhi RT, Mar H, Eron JJ, Cyktor JC, McMahon DK, Mellors JW.

J Infect Dis. 2022 06 15. 225(12):2163-2166. PMID: 35137129

CD4/CD8 Ratio and Cancer Risk Among Adults With HIV.

Castilho JL, Bian A, Jenkins CA, Shepherd BE, Sigel K, Gill MJ, Kitahata MM, Silverberg MJ, Mayor AM, Coburn SB, Wiley D, Achenbach CJ, Marconi VC, Bosch RJ, Horberg MA, Rabkin CS, Napravnik S, Novak RM, Mathews WC, Thorne JE, Sun J, Althoff KN, Moore RD, Sterling TR, Sudenga SL.

J Natl Cancer Inst. 2022 06 13. 114(6):854-862. PMID: 35292820

Reply to Bottanelli et al.

Cyktor JC, Bosch RJ, Mar H, Macatangay BJ, Collier AC, Hogg E, Godfrey C, Eron JJ, McMahon DK, Mellors JW, Gandhi RT.

J Infect Dis. 2022 06 01. 225(11):2051-2052. PMID: 35381084

Predictive value of CD8+ T cell and CD4/CD8 ratio at two years of successful ART in the risk of AIDS and non-AIDS events.

Serrano-Villar S, Wu K, Hunt PW, Lok JJ, Ron R, Sainz T, Moreno S, Deeks SG, Bosch RJ.

EBioMedicine. 2022 Jun. 80:104072. PMID: 35644125

Time to Viral Rebound After Interruption of Modern Antiretroviral Therapies.

Li JZ, Aga E, Bosch RJ, Pilkinton M, Kroon E, MacLaren L, Keefer M, Fox L, Barr L, Acosta E, Ananworanich J, Coombs R, Mellors JW, Landay AL, Macatangay B, Deeks S, Gandhi RT, Smith DM.

Clin Infect Dis. 2022 03 09. 74(5):865-870. PMID: 34117753

Impact of Tamoxifen on Vorinostat-Induced HIV Expression in Women on Antiretroviral Therapy (ACTG A5366:The MOXIE trial).

Scully EP, Aga E, Tsibris A, Archin N, Starr K, Ma Q, Morse GD, Squires KE, Howell BJ, Wu G, Hosey L, Sieg S, Ehui L, Giguel F, Coxen K, Dobrowlski C, Gandhi M, Deeks S, Chomont N, Connick E, Godfrey C, Karn J, Kuritzkes DR, Bosch RJ, Gandhi RT.

Clin Infect Dis. 2022 Feb 17. PMID: 35176755

Natural Killer Cell Receptors and Ligands Are Associated With Markers of HIV-1 Persistence in Chronically Infected ART Suppressed Patients.

Ivison GT, Vendrame E, Martínez-Colón GJ, Ranganath T, Vergara R, Zhao NQ, Martin MP, Bendall SC, Carrington M, Cyktor JC, McMahon DK, Eron J, Jones RB, Mellors JW, Bosch RJ, Gandhi RT, Holmes S, Blish CA.

Front Cell Infect Microbiol. 2022. 12:757846. PMID: 35223535

Frequency of post treatment control varies by antiretroviral therapy restart and viral load criteria.

Fajnzylber J, Sharaf R, Hutchinson JN, Aga E, Bosch RJ, Hartogensis W, Jacobson JM, Connick E, Volberding P, Skiest DJ, Margolis D, Sneller MC, Little SJ, Gulick RM, Mellors JW, Gandhi RT, Schooley RT, Henry K, Tebas P, Deeks S, Chun TW, Collier AC, Hecht FM, Li JZ.

AIDS. 2021 11 01. 35(13):2225-2227. PMID: 34127579

Suspected Immune-Related Adverse Events With an Anti-PD-1 Inhibitor in Otherwise Healthy People With HIV.

Gay CL, Bosch RJ, McKhann A, Moseley KF, Wimbish CL, Hendrickx SM, Messer M, Furlong M, Campbell DM, Jennings C, Benson C, Overton ET, Macatangay BJC, Kuritzkes DR, Miller E, Tressler R, Eron JJ, Hardy WD.

J Acquir Immune Defic Syndr. 2021 08 15. 87(5):e234-e236. PMID: 33929394